The QualityStocks Daily Monday, April 23rd, 2018

Today's Top 3 Investment Newsletters

QualityStocks (CSRH) +28.57%

OnPointStockAlert (BDCI) +21.21%

CannabisNewsWire (GOHE) +18.92%

The QualityStocks Daily Stock List

GulfSlope Energy, Inc. (GSPE)

Stockhouse, Morningstar, OTC Markets, InvestorsHub, MarketWatch, Equity Clock, and Financial Times reported on GulfSlope Energy, Inc. (GSPE),  and we report on the Company as well, here at the QualityStocks Daily Newsletter.

GulfSlope Energy, Inc. is an independent oil and natural gas company focusing on exploring offshore U.S. Gulf of Mexico. GulfSlope uses 2.2 million acres of 3D seismic data to identify high quality exploration prospects. The Company’s team has a track record of discovering and developing multi-billion dollar projects worldwide, with more than 300 years of combined experience in the oil and gas exploration industry. GulfSlope Energy is headquartered in Houston, Texas.    
  
GulfSlope Energy integrates its wide-ranging  3D seismic and geological databases. Therefore, it can identify leasing opportunities it believes have compelling characteristics  regarding size, geological attributes, in addition to potential for economic returns.  
  
The Company’s  portfolio has diversity in size, water depth, drilling depth, and risk profile. GulfSlope’s target is the Shelf Miocene  (2.2 MM Acres - 440 Blocks).

Concerning its Phase 1 Drilling Program, GulfSlope has high-graded five prospects with mean unrisked resource potential of 623 MMboe. It is looking to capitalize on strategic advantages provided by exploration work to identify undervalued producing assets.   

GulfSlope Energy has over 2 billion boe of net conventional recoverable resources. It has 23 lease blocks with 19 drilling prospects ranging from 30-280 MMboe.  Pertaining to the prospects, the average size is 120 MMboe.
 
The Company’s present focus is on pre-drill operations. It has a hybrid operating model with a preference to operate. The Miocene Subsalt Play – La Shelf, has large resource potential; is low to moderate risk; has moderate drilling and development costs; has shortened times to initial production, as well as enhanced economics. 

This past January, GulfSlope Energy and Texas South Energy, Inc. (TXSO) announced that they entered into a strategic partnership with Delek Group Ltd., an international independent oil and gas company headquartered in Israel. The Companies and Delek have mutually agreed to pursue oil and natural gas opportunities in the Gulf of Mexico.

The initial transaction of this partnership is the execution of a participation agreement. Delek GOM Investments LLC, a subsidiary of Delek, acquired rights to a 75 percent record title interest in nine prospects in the shallow waters of the Gulf of Mexico. GulfSlope will retain a 20 percent record title interest and Texas South will retain a 5 percent record title interest in each of the nine prospects.

Delek shall bear 90 percent of the gross cost and expense for each well until the test well reaches its goal depth. Subsequently, Delek will be responsible for 75 percent of the costs and expenses.  GulfSlope Energy and Texas South Energy will be responsible for their pro-rata ownership interest of all such remaining costs and expenses while partially carried and thereafter. Furthermore, Delek shall pay $1.5 million to the Companies (73 percent to GulfSlope and 27 percent to Texas South) upon the filing of each well's exploration plan with the BOEM.

In February 2018, GulfSlope Energy announced the execution of a drilling services contract with Atlantic Maritime Services LLC to secure and use the Ralph Coffman jackup rig for the Company's 2018 Gulf of Mexico drilling program.

GulfSlope anticipates spudding the initial well in mid-2018 on Vermilion Area, South Addition Block 378 (Canoe Shallow prospect) and the second well on Ship Shoal Area, South Addition Blocks 336 / 351 (Tau prospect) shortly after.

The expectation is that initial drilling on both prospects will be completed before the end of this year. The Ralph Coffman is a high specification jackup rig. It can drill to 35,000 feet. Atlantic Maritime Services is a wholly-owned subsidiary of Rowan Companies plc.

GulfSlope Energy, Inc. (GSPE), closed Monday's trading session at $0.067, down 1.03%, on 235,175 volume with 12 trades. The average volume for the last 60 days is 257,009 and the stock's 52-week low/high is $0.007/$0.13.

chart

Inspyr Therapeutics, Inc. (NSPX)

Zacks and BUYINS.NET reported earlier on Inspyr Therapeutics, Inc. (NSPX), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Inspyr Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Westlake Village, California. It is developing novel prodrug therapeutics for the treatment of cancer. Mipsagargin is its lead agent. Mipsagargin is in human clinical trials for patients with numerous different tumor types. Inspyr Therapeutics’ team has substantial pharmaceutical industry and scientific experience. The Company lists on the OTC Markets Group’s OTCQB.

Mipsagargin (G-202) is a prodrug in human clinical trials for patients with hepatocellular carcinoma (HCC, or liver cancer), glioblastoma (GBM, or brain cancer) and prostate cancer. Mipsagargin has been studied in a Phase 2 clinical trial in patients with hepatocellular carcinoma (liver cancer). It has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in this indication.

Mipsagargin is now undergoing evaluation in an open-label, single-arm, Phase II clinical study in patients with glioblastoma (brain cancer). Furthermore, it is undergoing evaluation in two Phase II clinical pilot studies in patients with prostate and clear cell renal cancer.

Inspyr Therapeutics has started the second development program for Mipsagargin as part of a combination therapeutic approach. This new program focuses on the treatment of gastric cancer.

Inspyr has commenced a preclinical study in gastric cancer PDX tumor models, which express varying levels of PSMA, the target of Mipsagargin. In this initial study, Mipsagargin will undergo evaluation initially in combination with paclitaxel.

In addition, the Company plans to evaluate Mipsagargin in combination with DC101 (Cyramza® surrogate antibody). Paclitaxel and Cyramza® are approved for the treatment of gastric cancer.

Inspyr Therapeutics is developing a novel technology platform. This platform combines a strong therapeutic (thapsigargin) with a patented prodrug delivery system that targets the release of drugs within solid tumors without the side effects of chemotherapeutic agents. The innovative platform technology has the potential to work across a range of drugs that precisely target different cancers.

In May 2017, Inspyr Therapeutics and Lewis and Clark Pharmaceuticals announced that they entered into an agreement to create an integrated company with a proprietary platform driving a pipeline of novel therapeutics. With this agreement, Inspyr Therapeutics will purchase Lewis and Clark in an all-stock transaction. Lewis and Clark Pharmaceuticals is a privately-held biotechnology company.

In October, Inspyr Therapeutics announced the start of a new investigator-sponsored preclinical study of its proprietary compounds generated via the Company’s adenosine receptor modulator (ARM) technology platform. The preclinical study will assess adenosine receptor agonists for the management of atherosclerosis.

Furthermore, in October, Inspyr Therapeutics announced the start of a new investigator-sponsored preclinical study of its proprietary adenosine receptor modulator (ARM) based compounds. The preclinical study is led by Elizabeth Kang, M.D., of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This study will assess these compounds for the prevention of graft versus host disease (GvHD), a potential side effect of allogeneic stem cell transplants.

Inspyr Therapeutics has fully-equipped, state-of-the-art organic and analytical chemistry laboratories in Charlottesville, Virginia. At these laboratories, a team of chemists and toxicologists have expertise in chemical synthesis and analysis, non-clinical dose formulation, plasma concentration analysis, assay development, and toxicology."

Inspyr Therapeutics, Inc. (NSPX), closed Monday's trading session at $0.01228, up 1.49%, on 55,000 volume with 4 trades. The average volume for the last 60 days is 98,580 and the stock's 52-week low/high is $0.012/$0.55.

chart

Medicine Man Technologies, Inc. (MDCL)

The Street, CFN Media Group, MarketWatch, Marketwired, and Stockhouse reported on Medicine Man Technologies, Inc. (MDCL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Medicine Man Technologies, Inc.  represents and licenses the cultivation and dispensary Intellectual Property (IP) of Medicine Man - a well-respected Tier III operator in Colorado. Medicine Man Technologies provides cultivation consulting services for cannabis growing technologies and methodologies. The Company is one of the nation’s top cannabis brand development and consulting enterprises.  Medicine Man Technologies has its head office in Denver, Colorado.

The Company works closely with industry-leading extraction partners. These partners provide the required licensing service support and formulations to assist customers with their planned deployment of a successful processing facility. 

Medicine Man Technologies is centering on working with clients’ to use its experience, technology, and training to help secure a license in states with newly emerging regulations. Moreover, the Company is concentrating on cultivation practices via  its deployment of Cultivation MAX, and eliminating the liability of single grower dependence.

Additionally, Medicine Man is continuing the expansion of its Brands Warehouse concept.  It additionally engages in retail operations of cannabis products. The Company also provides general business and referral management for other related service providers for its customers. It cultivates and sells by way of its parent company Medicine Man Denver, the largest cultivation/retail facility in Colorado.

Medicine Man Technologies’ risk-averse cannabis cultivation technology delivers consistent, high quality, high yield production within a clean-room style environment.  Its state-of-the art dispensary model ensures patients and consumers have safe and secure access to  an array of medical and/or recreational cannabis products.

This past February, Medicine Man Technologies and Solis Tek, Inc. announced a cooperative agreement. Solis Tek will become Medicine Man Technologies' recommended supplier of High Intensity Discharge (HID) lighting technologies for its present and prospective consulting and sales relationships. The recommended status includes Solis Tek Lighting as its specified cultivation lamp fixture in its equipment lists and facility designs.

Recently, Medicine Man Technologies reported financial results for the year ended December 31, 2017. The Company’s financial highlights - 12 Months of Operations – include Revenues increasing by 459 percent to $3,529,584 in Fiscal 2017, from $631,456 in 2016. At December 31, 2017, Medicine Man's Cash position was $748,715, versus $351,524 at December 31, 2016.

Regarding its business highlights -12 Months of Operations - Medicine Man Technologies completed and fully integrated three acquisitions. These are Pono Publications, Success Nutrients, and the Denver Consulting Group. In addition, the Company served 47 active clients in Fiscal Year 2017, more clients overall than it had generated since its inception in April 2014.

Since its last client update last month, Medicine Man Technologies entered into five new license and/or service agreements. The Company highlighted its single Iowa client’s win of two dispensary licenses that was announced in late March 2018 by its client. Furthermore, among the new license agreements is a considerable new Cultivation MAX Client in Nevada that expects to commence construction around mid-year for the rehabilitation of more than 100,000 sq. ft. of existing space.

Medicine Man Technologies, Inc. (MDCL), closed Monday's trading session at $2.06, even for the day, on 31,683 volume with 74 trades. The average volume for the last 60 days is 46,482 and the stock's 52-week low/high is $0.92/$3.40.

chart

Real Goods Solar, Inc. (RGSE)

MarketWatch, InvestorsHub, Stock News Gazette, Stock Twits,  Investor Place, Barchart, and TradingView reported on Real Goods Solar, Inc. (RGSE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Real Goods Solar, Inc.’s RGS Energy (America’s Original Solar Company®) operates as a residential and small business commercial solar energy engineering, procurement, and construction company in the U.S. The Company has installed more than 25,000 solar energy systems for homes,  businesses,  schools,  government facilities, and utilities across the nation. This has totaled greater than 260 megawatts of clean energy. Real Goods Solar  (RGS Energy) is headquartered in Denver, Colorado.  RGS Energy is the Company’s registered trade name.

Furthermore, the Company is the exclusive manufacturer of POWERHOUSE™. This is an innovative in-roof solar shingle using technology developed by The Dow Chemical Company. RGS Energy entered into an exclusive domestic and global license agreement with The Dow Chemical Company for the POWERHOUSE™ solar shingles system. RGS will lead all commercial activities for the product. This includes supply chain management, marketing, sales, installation, and warranty.

Pertaining to RGS Energy’s business segments, the Solar Division comprises RGS Energy’s Residential and Sunetric business segments. The Corporate segment includes administrative costs associated with administrative services, legal settlements, legal, information systems, and accounting and finance. Commencing on September 29, 2017, POWERHOUSE™ is the Company’s new business segment.

RGS Energy announced in November of 2017 the on-time launch of Solar 365™. This is its new mobile software and online dashboard suite. New and prospective customers can easily navigate Solar 365™. They can access information and documents regarding their planned solar installation wherever and whenever it is convenient. After installation, customers can easily access and view their cost savings and production stats in kilowatts and dollars earned if net metering.

RGS Energy has won a 2018 Muse Creative Award in the mobile app category, Rose Gold level, for its cloud-based customer and business solution, RGS 365™. The Muse Creative Awards is a global competition. It recognizes creative professionals who inspire through concept, writing or design using traditional or electronic media. RGS Energy has partnered with industry leaders Risen Energy Co., General Polymers Thermoplastic Materials, and Creative Liquid Coatings to commercialize the RGS POWERHOUSE™ 3.0 Solar Shingle. This is a unique and visually stunning solar shingle system utilizing technology developed by The Dow Chemical Company.

Risen Energy is a Top 10 Tier 1 solar cell and module manufacturer located in China. General Polymers Thermoplastic Materials is one of the quickest growing multi-national thermoplastic resin distributors serving custom injection molders in North America. Creative Liquid Coatings provides premier capabilities in injection molding and paint finishing serving the consumer and industrial products markets.

Real Goods Solar, Inc. (RGSE), closed Monday's trading session at $0.961, down 2.39%, on 114,276 volume with 237 trades. The average volume for the last 60 days is 285,463 and the stock's 52-week low/high is $0.6001/$3.25.

chart

Terra Tech Corp. (TRTC)

Epic Stock Picks, Stock of the Week, Stockhouse, Street Register and Penny Stock Tweets reported on Terra Tech Corp. (TRTC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Terra Tech Corp. is a vertically integrated cannabis-focused agriculture company. The Company operates through manifold subsidiary businesses. These include Blüm, IVXX Inc., Edible Garden, and MediFarm LLC. Terra Tech’s dedication is to cultivating and providing the highest quality medical cannabis and other agricultural products. Terra Tech has its corporate headquarters in Irvine, California.

The Company is integrating the best of the natural world with technology to create sustainable solutions for medical cannabis production, extraction and distribution, plant science research and development, food production, and Closed Environment Agriculture (CEA).

Blüm offers a wide choice of cannabis products. These include flowers, concentrates, and edibles via its Oakland, California and numerous Nevada locations.

IVXX, Inc. is a wholly-owned subsidiary of Terra Tech. IVXX produces cannabis-extracted products for regulated medical cannabis dispensaries across California and medical and adult-use dispensaries in Nevada.

Terra Tech’s wholly-owned subsidiary is Edible Garden. It cultivates a first-rate brand of local and sustainably grown hydroponic produce. It sells by way of major grocery stores including ShopRite, Walmart, Ahold, Aldi, Meijer, Kroger, Stop & Shop and others across the nation.

Terra Tech's MediFarm LLC subsidiaries concentrate on medical and adult-use cannabis cultivation. MediFarm subsidiaries also focus on permitting businesses throughout Nevada.

For 2018, Terra Tech’s capital expenditures will be directed toward the build out of its cultivation, extraction and retail infrastructure in California, Nevada and New Jersey. The Company has secured a $40 million investment. It is to be made in eight tranches of $5 million over 24 months.

In Oakland, California, Terra Tech is building a 13,000-square-foot cultivation facility. It will have the capacity to produce up to one metric ton, or 2,000 pounds, of cannabis annually. The facility received its provisional cultivation permits in Q2 of 2017. The expectation is that it will be completely operational by mid-2018.

Terra Tech continues to explore M&A (Mergers and Acquisitions) opportunities in California. By way of organic growth and its M&A strategy, it expects to attain a footprint within the California market that allows for the production of up to 20,000 pounds annually of cannabis.

In Nevada, Terra Tech has completed construction of a new 30,000 square foot cannabis cultivation facility in Sparks and a 15,000 square foot cannabis extraction facility in Reno via agreements with NuLeaf. The Company is awaiting final State approval to commence IVXX production at the Reno facility.

In New Jersey, construction is taking place for a major new pack house to distribute salads and leafy greens for the Company’s subsidiary, Edible Garden.

Terra Tech Corp. (TRTC), closed Monday's trading session at $2.96, down 6.03%, on 630,822 volume with 962 trades. The average volume for the last 60 days is 6,295,830 and the stock's 52-week low/high is $0.138/$3.48.

chart

BioSig Technologies, Inc. (BSGM)

DreamTeamNetwork, Wall Street Resources, Pumps and Dumps, The Wall Street Transcript, Goldman Small Cap Research, PennyStockLocks.com, Stock Commander,  SeeThruEquityResearch, Stock News Now, ResearchOTC, StockRockandRoll, and BUYINS.NET reported previously on BioSig Technologies, Inc. (BSGM), and today we report on the Company, here at the QualityStocks Daily Newsletter.

BioSig Technologies, Inc. is a medical device company developing PURE EP™. This is a proprietary technology platform designed to improve the clinical outcomes of electrophysiology (EP) procedures. The Company’s aim is to seek Food and Drug Administration (FDA) 510(k) approval for the PURE EP™ System. It is preparing to commercialize the PURE EP™  System.

BioSig Technologies has its headquarters in Los Angeles, California centered on research and development  (R&D).  The Company lists on the OTC Markets Group’s OTCQB.

This past February,  BioSig Technologies announced that it is opening a new office in Austin, Texas. The new offices will complement its headquarters in Los Angeles and will become an operational hub hosting administration, field engineering, as well as sales.

The PURE EP™ is a next-generation surface electrocardiogram and intracardiac multichannel signal acquisition and analysis system. The design of it is to help electrophysiologists in making clinical decisions in real-time through acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data, which  may be used to guide the electrophysiologists in identifying ablation targets (areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia)).

BioSig Technologies  has achieved proof of concept validation and tested its prototype at the University of California at Los Angeles  (UCLA) Cardiac Arrhythmia Center. It has performed pre-clinical studies at Mayo Clinic in Minnesota.

Furthermore, the Company is collaborating with other prestigious cardiac arrhythmia centers. These include Texas Cardiac Arrhythmia Institute, UH Case Medical Center in Cleveland,  Ohio,  and Mount Sinai Medical Center in New York.

BioSig Technologies has also expressed its plan to enter the developing field of bioelectric medicine. Moreover, it has partnered with Minnetronix on technology development. BioSig Technologies is working toward FDA 510(k) clearance and CE Mark for the PURE EP System.

Last month, BioSig Technologies announced that it filed 510(k) application to the U.S. Food and Drug Administration (FDA) for its first product, PURE EP™ System.

Mr. Kenneth L. Londoner, Chairman and Chief Executive Officer of BioSig Technologies, said, “Our Company’s mission is to improve the standards of patient care worldwide. Submission of 510(k) application is a major milestone, which, once completed, will allow us to bring the PURE EP System to the EP community. Patient-centred innovation is at the heart of what we do, and we will continue to work rigorously to address unmet clinical needs.”

BioSig Technologies, Inc. (BSGM), closed Monday's trading session at $2.03, up 6.84%, on 140,895 volume with 186 trades. The average volume for the last 60 days is 73,051 and the stock's 52-week low/high is $1.23/$2.36.

chart

Rocky Mountain High Brands, Inc. (RMHB)

SmallCapVoice, Promotion Stock Secrets, SizzlingStockPicks, WallstreetSurfers, Penny Picks, ProTrader, Winston Small Cap, Fortune Stock Alerts, PennyPickAlerts, and Damn Good Penny Picks reported earlier on Rocky Mountain High Brands, Inc. (RMHB), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Rocky Mountain High Brands, Inc. is a consumer goods company with its corporate headquarters in Dallas, Texas. Its specialty is brand development of health conscious, hemp-infused, food and beverage products and naturally high alkaline water. Rocky Mountain High Brands has now launched its naturally high alkaline spring water, Eagle Spirit Spring Water. Rocky Mountain High Brands lists on the OTC Markets Group’s OTCQB.

Rocky Mountain employs a hybrid distribution model. This model takes advantage of distribution contacts and brokers, and direct relationships with wholesalers and retailers to expand strategically into new markets. The Company engages in sales and distribution through online retailers. It presently distributes its products to a variety of retail locations, from grocery to convenience to warehouse stores, throughout the United States.

At present, the Company markets a lineup of four naturally flavored hemp-infused beverages. These are Citrus Energy, Black Tea, Mango Energy and Lemonade. In addition, Rocky Mountain High Brands markets a low-calorie Coconut Lime Energy drink. Moreover, it offers hemp-infused 2 oz. Mango Energy Shots and Mixed Berry Energy Shots.

Rocky Mountain High Brands has launched its strong GPS based geofencing software advertising system in the Los Angeles, California market. Geofencing is the practice of utilizing Global Positioning (GPS) or radio frequency identification (RFID) to define a geographic boundary.

The Company’s geofencing software package underwent development by the Beasley Broadcast Group's (BBGI) Digital Marketing Solutions division. The design of the software package is to interface with mobile devices when a consumer is within proximity of a Rocky Mountain High retailer.

In March of this year, Rocky Mountain High Brands announced that it entered into an agreement with L and H Resort Systems to acquire a former Catskill Mountain resort facility situated on a natural spring. The Company’s plan is to repurpose the resort into a Bottling and Canning Plant for Rocky Mountain High Brands.

Last month, Rocky Mountain High Brands announced that it has retained Mr. Jonathan Miller, Member-in-Charge of the Lexington office of the law firm of Frost Brown Todd LLC, to assist the Company in exploring entry into the hemp-derived CBD (cannabidiol) market. Frost Brown Todd is a full-service law firm. It has over 500 attorneys in eight states (including Texas). It has been instrumental in securing federal and state legislation, which have advanced the growth of the developing industrial hemp and CBD industries, and in helping companies navigate state and federal legal and regulatory issues.

Rocky Mountain High Brands also announced in October that its subsidiary, Rocky Mountain High Water Company, LLC, has a non-gaming vendor registration license with Osage Casinos, the gaming enterprise of the Osage Tribe, to sell its Eagle Spirit Spring Water in their retail establishments. Under the license, Eagle Spirit Spring Water is now selling in this market. Osage Casinos now has seven gaming centers across Osage County. These include Tulsa, Bartlesville, Sand Springs, Ponca City, Skiatook, Hominy and Pawhuska.

Rocky Mountain High Brands, Inc. (RMHB), closed Monday's trading session at $0.0137, even for the day, on 8,193,041 volume with 174 trades. The average volume for the last 60 days is 15,107,614 and the stock's 52-week low/high is $0.0053/$0.111.

chart

Valeritas Holdings, Inc. (VLRX)

StockTwits, Zacks, Street Insider, Barchart, 4-Traders, Simply Wall St, Stockwatch, InvestorsHub, The Street, and Investor Network reported on Valeritas Holdings, Inc. (VLRX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Valeritas Holdings, Inc. is a commercial-stage medical technology company. It offers patients with type 2 diabetes the V-Go® Wearable Insulin Delivery device. This is a simple, all-in-one insulin delivery option. The V-Go® Wearable Insulin Delivery device is worn like a patch. It can eliminate the need for taking numerous daily shots.

Listed on the NasdaqCM, Valeritas Holdings is headquartered in Bridgewater, New Jersey. The Company operates its research and development (R&D) functions in Marlborough, Massachusetts.

Valeritas Holdings’ flagship product, V-Go® Wearable Insulin Delivery device, is a wearable, basal-bolus insulin delivery device for patients with type 2 diabetes. It enables patients to administer a continuous preset basal rate of insulin over 24 hours.

In addition, it provides discreet on-demand bolus dosing at mealtimes. The V-Go® Wearable Insulin Delivery device is the only basal-bolus insulin delivery device on the market today purposely designed keeping in mind the needs of type 2 diabetes patients.

Last week, Valeritas Holdings announced that it signed an exclusive distribution agreement with AMSL Diabetes and NZMS Diabetes. This distribution agreement is for the commercialization of its V-Go® Wearable Insulin Delivery device in Australia and New Zealand. With this agreement, AMSL Diabetes and NZMS Diabetes will have the rights to promote, market, as well as sell the V-Go to diabetes clinics and patients in Australia and New Zealand.

Valeritas Holdings will retain responsibility for product development, regulatory approval, quality management, and manufacturing.  AMSL Diabetes and NZMS Diabetes will be responsible for sales, marketing, customer support and distribution activities in Australia and New Zealand.

In addition, last week, Valeritas Holdings announced it entered into an agreement with Glooko, a leader in diabetes data management. Under the agreement, Valeritas will provide future V-Go SIM (Simple Insulin Management) users with Glooko’s cloud-based mobile and web diabetes data management platform to help track and analyze their diabetes care plan. As well, users can share their data with their providers.

V-Go SIM is a new, long-lasting accessory. It will snap onto the Company’s flagship product, V-Go® Wearable Insulin Delivery device. The design of it is to provide one-way Bluetooth communication from the V-Go SIM to a patient’s smart device.

The V-Go SIM's onboard electronics will provide information concerning V-Go’s use and wirelessly transmit the data through a V-Go SIM application (app) on a mobile device. The V-Go SIM is investigational. The expectation is that it will not be available for full commercial use in the United States until the first half of 2019.

Valeritas Holdings, Inc. (VLRX), closed Monday's trading session at $2.55, down 18.27%, on 5,728,053 volume with 23,473 trades. The average volume for the last 60 days is 169,305 and the stock's 52-week low/high is $1.189/$7.30.

chart

Versus Systems, Inc. (VRSSF)

Barchart, TradingView, and InvestorsHub reported earlier on Versus Systems, Inc. (VRSSF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Versus Systems, Inc. has developed a proprietary in-game conditional prizing and promotions engine. This engine enables players to compete for and win real prizes from brands that they care about while playing their favorite games. Essentially, the Company’s white-label platform gives players the opportunity to play for the things they love, inside of the games they love.  Versus Systems is headquartered in Vancouver, British Columbia. The Company lists on the OTC Markets’ OTCQB.

Versus Systems enables game developers and publishers to provide players with prizes that players can win inside their favorite games. This adds engagement and also a new dimension to gameplay. Company prizing includes gear, apparel, tickets, energy drinks, and downloadable content from brands such as Tier 1, Han Cholo, Rockstar Energy Drink, and others. 

Versus Systems was named #13 on the 100 Top Companies for Millennial Women by leading women’s platform Mogul. The Company received recognition alongside Nike, Pinterest, and Deloitte for their efforts to attract, promote, and empower women in the workplace. 

Versus Systems announced this year that it partnered with 704Games to provide in-game prizing in their upcoming titles.  704Games is working with the Company’s prizing and promotions platform to provide players with opportunities for in-game prizing and real-world rewards in their upcoming titles on mobile and console. 

704Games released NASCAR Heat Mobile this past spring. This is the first authentic NASCAR racing game on mobile to feature 40 stock cars racing at the same time. Moreover, 704Games earlier announced their NASCAR Heat 2 for Xbox One, Playstation 4, and PC.

Last month, Versus Systems announced it is developing a blockchain-enabled version of its conditional prizing platform.

Mr. Matthew Pierce, Versus Systems’ Founder and Chief Executive Officer, said, “Versus has been including bitcoin and other cryptocurrencies as potential prizing solutions in all of our IP filings from as far back as 2014. We believe in the power of the blockchain as a mechanic for securing identity records, and records of gameplay – rich data that we want to ensure is easy to secure at the highest level, easy to personalize, and straightforward to audit when necessary to ensure true outcomes.”

This month, Versus Systems announced a partnership with IDW Media Holdings, Inc. (IDWM) to expand the Versus in-game prize offerings for video gamers.  Players will compete in-game for access to IDW’s comprehensive portfolio. IDW Media Holdings publishes comics and graphic novels for Star Trek, Transformers, Teenage Mutant Ninja Turtles, My Little Pony, and more.

Versus Systems, Inc. (VRSSF), closed Monday's trading session at $0.2478, up 7.97%, on 4,150 volume with 2 trades. The average volume for the last 60 days is 9,175 and the stock's 52-week low/high is $0.20/$0.6042.

chart

Accelerize, Inc. (ACLZ)

Buzz Stocks, Penny Pick Finders, StockOodles, Greenbackers, ResearchOTC, StockRockandRoll, PennyStockLocks, Planet Penny Stocks, PennyStockProphet, StockOnion, and FeedBlitz reported previously on Accelerize, Inc. (ACLZ), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Accelerize, Inc. provides marketing technology solutions that transform the way advertisers leverage their digital advertising data. CAKE is a division of Accelerize and is the Company’s digital marketing software division. CAKE provides a cloud-based solution to track and analyze the performance of digital marketing Return on Investment (ROI), in real-time. Accelerize is headquartered in Newport Beach, California.

The Company’s CAKE is a software-as-a-service (SaaS) enterprise platform. It provides online tracking, reporting, lead distribution, and analytics solutions for advertisers, online marketers, affiliate marketers, and lead generators. With CAKE, one can track and optimize affiliate traffic. A user can also collect, validate and distribute leads. Furthermore, one can gather and analyze multi-channel data.

Accelerize offers CAKE for Advertisers and CAKE for Networks. CAKE for Advertisers is a SaaS solution. It enables brand advertisers to unify the tracking, attribution, and optimization of digital marketing spend across search, display, email, video, social, affiliate, and other marketing channels.

CAKE for Networks is a marketing solution for affiliate networks. CAKE by Accelerize is based in Newport Beach, with operations in New York, London, India, and Sydney, Australia.

Last month, Accelerize and its digital marketing software division CAKE announced that India-based ADZ Junction Media is using CAKE’s SaaS Marketing Intelligence platform to power its fast growing worldwide digital marketing and media hub. ADZ Junction joins a growing roster of CAKE clients operating in India. This includes several top advertising networks and ecommerce providers.

ADZ Junction Media provides a broad spectrum of digital marketing services spanning creative support and also campaign management across affiliate, content, influencer, and search, social and video channels.

In addition, in December, Accelerize and CAKE announced that it plans to increase the scope of MarketingIntelligence.com, to encompass an online content hub spotlighting customer journey analytics, multi-touch attribution, plus developing international digital marketing trends and news. Additionally, MarketingIntelligence.com offers information for marketers interested in learning more about Journey by CAKE, which is an enterprise software solution specifically designed to provide accurate, real-time insight into every step of the customer journey. Journey by CAKE delivers advanced analytics, multi-touch attribution and seamless integrations with popular media platforms through a central, cloud-based interface.

This week, Accelerize and CAKE announced the Company’s participation as a sponsor and exhibitor at Affiliate Summit West, to take place January 7-9, 2018 at the Paris Las Vegas Hotel. The event attracts greater than 6,000 attendees, exhibitors and thought leaders from more than 70 countries.

Accelerize, Inc. (ACLZ), closed Monday's trading session at $0.38, up 11.73%, on 54,085 volume with 12 trades. The average volume for the last 60 days is 22,655 and the stock's 52-week low/high is $0.25/$0.40.

chart

Rezolute, Inc. (RZLT)

Street Insider, The Street, Stockopedia, Dividend Investor, Simply Wall St, OTC Markets, MarketWatch, Morningstar, InvestorsHub, 4-Traders, Barchart, Stockhouse, and YCharts reported on Rezolute, Inc. (RZLT), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Rezolute, Inc. is a clinical stage biopharmaceutical company. It specializes in the development of innovative drug therapies for metabolic and orphan diseases. The Company formerly went by the name AntriaBio, Inc. It changed its corporate name to Rezolute, Inc. in December 2017. Rezolute is headquartered in Louisville, Colorado.

Rezolute is advancing a diverse pipeline. This pipeline includes RZ358 (Phase 2), an antibody for the ultra-orphan indication of Congenital HyperInsulinism (CHI), with an abbreviated path-to-market strategy. In addition, the pipeline includes AB101 (Phase 1). This is a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management through reducing the therapeutic burden for patients and improving compliance.  

Additionally, the Company’s pipeline includes a Plasma Kallikrein Inhibitor (PKI) portfolio with two lead compounds, RZ402 targeting Diabetic Macular Edema (DME) and RZ602 targeting Hereditary Angioedema (HAE), an orphan indication. 

Rezolute and XOMA Corporation have executed a license agreement. This agreement provides Rezolute with the exclusive international rights to develop and commercialize RZ358 (formerly XOMA 358) for Congenital Hyperinsulinism (CHI), an ultra-orphan indication. XOMA is a pioneer in the discovery, development, and licensing of therapeutic antibodies. 

RZ358 is a first-in-class fully human monoclonal antibody. It counteracts the effects of elevated insulin through allosteric modulation of the insulin receptor. This makes it well-suited as a therapy for severe, persistent hypoglycemia caused by hyperinsulinemic conditions such as CHI.

Earlier this month, Rezolute announced that Christine Ferrara, M.D., Ph.D., has joined the Company as Director of Clinical Development. Dr. Ferrara will support clinical development of Rezolute’s pipeline generally.

In addition, Dr. Ferrara will have chief responsibility for the clinical development program of RZ358 for Congenital Hyperinsulinemia (CHI). CHI is a life-threatening ultra-orphan disease with a considerable unmet need for safer and more effective therapies.

Dr. Ferrara joins Rezolute as the Company prepares to start a Phase 2b study of RZ358. Dr. Ferrara stated, “I am excited to join Rezolute as I believe RZ358 has the potential to become the primary treatment option for patients suffering with CHI, for whom there is often no adequate treatment. In addition, I look forward to developing therapies that intersect with my area of patient-care and research focus, while continuing to care for patients and families affected by CHI.”

Rezolute, Inc. (RZLT), closed Monday's trading session at $0.53, even for the day. The average volume for the last 60 days is 12,135 and the stock's 52-week low/high is $0.451/$0.99.

chart

The QualityStocks Company Corner

AnalytixInsight Inc. (TSX.V: ALY) (OTCQB: ATIXF)

The QualityStocks Daily Newsletter would like to spotlight AnalytixInsight Inc. (ATIXF).

Artificial intelligence company AnalytixInsight Inc. (TSX.V: ALY) (OTCQB: ATIXF) this morning announced that it will present at the Planet MicroCap Showcase at 1:30 pm PST on Wednesday, April 25, 2018. To view the full press release, visit: http://nnw.fm/Nkp37.

AnalytixInsight Inc. (TSX.V: ALY) (OTCQB: ATIXF) is an artificial intelligence (AI) company that transforms data into knowledge. The company has developed a proprietary, machine-learning technology that algorithmically analyzes big data and distills it into actionable insights. AnalytixInsight has strategic initiatives in fintech, blockchain and workflow analytics, and its technology is scalable and extendable to virtually any data-driven industry such as sports, communications, healthcare, insurance or government.

The company’s flagship product – CapitalCube.com – is a financial portal providing comprehensive company analysis including on-demand fundamental research, portfolio evaluation and screening tools on over 50,000 global equities and North American ETFs. CapitalCube’s online portal is designed to empower investment ideas by providing in-depth analysis, peer-to-peer performance evaluations, accounting and earnings reports, dividend strength and AI-supported information about likely corporate actions such as dividend changes, share buybacks and acquisitions. AnalytixInsight provides a robust technology that is frequently rebalanced to maintain a desired risk profile, matching risk to ideal ETF exposure, with regular compliance reporting.

CapitalCube’s freemium pricing model allows free access to basic financial information, with additional in-depth analysis and predictive analytics provided at a rate of $25 per month, and customized peer analysis for $300 per month. CapitalCube publishes 3,000 articles daily and has multi-language capabilities. Thomson Reuters and Africa Investor have recently been added to the growing network of content partnerships that already includes Euronext NV, Yahoo Finance and The Wall Street Journal.

Euclides Technologies is a subsidiary company focused on Field Service Management software solutions, led by a team with decades of experience in developing and implementing workforce management solutions for large global corporations. With worldwide customers representing over 100,000 field service personnel across multiple industries, Euclides Technologies has a deep understanding of the increasing amount of data generated within the industry, as well as the analytics solution offerings to transform that data into knowledge.

MarketWall is a Fintech subsidiary that develops integrated software solutions as part of an ecosystem of smart devices that includes PCs, tablets, smart phones, wearable mobile devices and Smart TV. AnalytixInsight Inc. has joint ownership in MarketWall together with Intesa Sanpaolo, Italy’s largest retail bank which has over 4,000 branches and a market capitalization of $40 billion Euros. MarketWall is expected to deploy its real-time stock trading and mobile banking app to Intesa Sanpaolo’s 12.6 million customers in six European countries during 2018. The mobile stock trading application will directly interface with Intesa Sanpaolo’s established MarketHub trading platform. As a Samsung Global Partner, the MarketWall app is preloaded in mobile devices in certain areas in Europe.

AnalytixInsight is currently evaluating and pursuing Blockchain initiatives which are contiguous with its artificial intelligence platform, to use a distributed ledger technology to reduce transaction costs and settlement times for its users, partners, and subsidiaries. The Company believes these initiatives will enhance current revenues being received from existing multi-year agreements with its partners.

AnalytixInsight Inc. (ATIXF), closed the day's trading session at $0.345, up 11.22%, on 15,800 volume with 6 trades. The average volume for the last 60 days is 8,182 and the stock's 52-week low/high is $0.15/$0.6898.

Recent News

chart

Zenergy Brands, Inc. (ZNGY)

The QualityStocks Daily Newsletter would like to spotlight Zenergy Brands, Inc. (ZNGY).

In stark contrast to the status quo, slashing total utility costs by 20 to 60 percent, Zenergy Brands, Inc. (OTC: ZNGY) is disrupting the established order in utility expenses.

Zenergy Brands, Inc. (ZNGY) is the nation’s leading next-generation energy and technology company operating in the emerging smart energy, conservation, and utility industries. Headquartered in Texas, Zenergy provides an entire suite of conservation-based products and services that enable clients to achieve sustainability goals, reduce carbon emissions and improve their bottom line. The company’s cutting-edge Zero Cost Program™ reduces utility expenses by 20 percent to 60 percent by offering energy conservation, smart controls, and efficiency-based products and services to residential, commercial, industrial and municipal end-use customers.

The Zero Cost Program™ is a financing mechanism that allows customers to reduce water, natural gas and electricity expenses by implementing proven conservation technologies at no out-of-pocket cost. The Zero Cost Program™ enriches businesses by immediately reducing energy consumption through the use of smart controls, building automation, LED lighting solutions, refrigeration optimization, efficient water systems, EC motor controls, demand-side management and load factor correction.

A unique Managed Energy Services Agreement (“MESA”) allows a portion of these utility savings to be retained by Zenergy’s partner financing the upgraded, retrofit equipment and installation costs until a specified repayment period ends. After that, clients reap all the financial rewards of the technologies implemented, which Zenergy estimates should range between 25 percent and 45 percent of total utility costs.

Residential customers seeking cost-effective energy savings can also choose from a suite of “Smart Home” products including home automation, security monitoring, and energy conservation services that can be controlled 24/7 from the comfort and convenience of their smartphones or internet-connected smart devices. Zenergy’s residential program offers partnership opportunities for homebuilders and residential, multi-family real estate developers to provide smart home technologies to high-end customers.

Zenergy Brands’ acquisition of Enertrade Electric LLC, a fully operating, licensed Texas-based Retail Electric Provider (REP), further increases the company’s value proposition. Zenergy CEO Alex Rodriguez said this new subsidiary adds an essential complementary service to the company’s suite of smart energy products and services.

“Since our founding, our vision has been to converge smart controls (home and building automation) with energy conservation and retail energy to deliver the comprehensive smart energy service to customers,” Rodriguez said.

On a global scale, residential and commercial buildings account for nearly 45 percent of the world’s total energy consumption. Improving the energy efficiency of these homes and buildings is often a more affordable way to reduce harmful gas emissions while minimizing the need for new energy production. According to Navigant Research, global revenue for energy-efficient commercial building retrofits alone is expected to grow from $71.4 billion in 2016 to $100.8 billion in 2025. At the same time, the energy-efficient devices market is expected to reach a market size of $908 billion by 2022. Increasing demands for reduction in energy consumption and greenhouse gas emissions along with concerns over climate change are contributing factors driving the market’s overall growth.

Zenergy Brands, Inc. (ZNGY), closed the day's trading session at $0.0092, up 5.75%, on 2,784,267 volume with 33 trades. The average volume for the last 60 days is 3,094,909 and the stock's 52-week low/high is $0.0027/$0.045.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX), a drug delivery platform innovator, is pleased to announce that it has commenced a clinical study in Europe to evaluate the cardiovascular and cognitive health effects of Lexaria's high absorption TurboCBD™ capsules.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.36, up 8.89%, on 327,961 volume with 294 trades. The average volume for the last 60 days is 226,237 and the stock's 52-week low/high is $0.27/$2.54.

Recent News

chart

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

ChineseInvestors.com Inc. (OTCQB: CIIX), the premier financial information website for Chinese-speaking investors, today announces the expansion of its cryptocurrency and blockchain technology media and internet education business into China.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed the day's trading session at $0.52, up 6.12%, on 67,204 volume with 31 trades. The average volume for the last 60 days is 63,017 and the stock's 52-week low/high is $0.40/$1.58.

Recent News

chart

Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF)

The QualityStocks Daily Newsletter would like to spotlight Sunniva, Inc. (SNNVF).

Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) seems destined for a future as bright as its name. According to a recent article, titled ‘Who will Dominate California -- the World’s Largest Cannabis Market?’ (http://cnw.fm/Lc8w7), "Sunniva’s once-in-a-lifetime opportunity to become one of California’s dominant cannabis companies cannot be over-emphasized."

Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF) is a vertically integrated medical cannabis company operating in the world’s two largest cannabis markets – Canada and California – committed to delivering safe, consistent, high-quality products and services. Sunniva operates through its wholly owned subsidiaries: Sunniva Medical Inc., CP Logistics, LLC, Natural Health Service Ltd., and Full-Scale Distributors, LLC. Sunniva’s vision is to become the lowest cost, highest quality cannabis producer in the markets it serves by building large scale purpose-built cGMP-compliant greenhouses, offering best quality assurance with cannabis products free from pesticides, providing better patient and doctor access to cannabis education, and sourcing better therapeutic delivery devices.

The company is establishing sophisticated distribution channels, including Sunniva’s ownership of Natural Health Services cannabis clinics in Canada with over 95,000 active patients, to purchase the significant quantities of high quality Sunniva-branded and Sunniva private-labeled cannabis products.

Sunniva is an ancient English name which means, “Gift of the Sun.” Sunniva’s team of horticulturists, scientists and engineers is helping to set best practices for the industry, believing that sun-grown, solar-powered cultivation is the most sustainable and cost-effective way to grow high-quality, premium cannabis.

The Sunniva Family includes:

CP Logistics, LLC

Through its subsidiary, CP Logistics LLC, Sunniva is developing Sunniva Campus, a state-of-the-art, purpose-built greenhouse facility in Cathedral City, California. This modern purpose-built, agri-technology greenhouse will adhere to the Current Good Manufacturing Practice (cGMP) regulations that assure proper design, monitoring and control of manufacturing processes and facilities.

Phase 1 of the project includes a fully funded 325,000 square foot greenhouse capable of producing 60,000 kg per year of dry cannabis at capacity with operations commencing Q3 2018. Approximately 30 percent of initial total production will be converted into oils and extracts. Phase 2 is expected to increase the greenhouse by 165,000 square feet and grow production by about 40,000 kg per year.

These uniquely sealed greenhouses are designed to deploy custom, automation assembly line cultivation processes at a large scale. Energy consumption will be reduced while utilizing the energy of the sun and microclimatic controls to provide precise growing conditions. The greenhouse will recirculate air for more efficient climate control, and the company’s Integrated Pest Management System is designed to ensure every plant grown is certified clean and free of all contaminants and pesticides.

Sunniva Medical Inc.

Sunniva Medical Inc. is designing and preparing to break ground on the Sunniva Canada Campus encompassing 700,000 square feet of purpose-built cGMP greenhouse facilities in the Okanagan Valley, British Columbia. The total campus is expected to produce 100,000 kg of premium medical cannabis a year plus additional trim used for extraction. This facility will produce pesticide-free products and will convert trim to extracted products such as cannabis oil that can be used for drug delivery formats such as capsules, dissolvable strips, vaporization cartridges, tinctures and creams.

Sunniva and Canopy Growth Corporation (“Canopy Growth”) recently announced a large take or pay supply agreement. Under the terms of the agreement, Canopy Growth will purchase up to 45,000 kilograms of dried cannabis annually commencing Q1 2019, which includes the distribution of Sunniva branded products. Sunniva Medical is a late-stage applicant under Canada’s ACMPR and is in the final review stage of the process.

Natural Health Services Ltd.

Natural Health Services (“NHS”) owns and operates a network of eight medical clinics in Canada specializing in medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). NHS connects licensed producers to their 21 physicians and patients with its proprietary SPARK software which utilizes a software-as-a-service revenue model. To date, there are 27 integrated licensed producers utilizing the SPARK software.

In-house physicians specializing in the endocannabinoid system provide expert consultation, education and recommendations for targeted phytoceutical remedies and wellness plans to improve the quality of life for all patients. NHS enjoys a long-term relationship with patients due to the quality of its physician-patient experience. A rapidly expanding NHS cannabis clinic network serves 94,000 active patients in Canada. NHS has also initiated a pilot program with a national pharmacy chain to aggregate more patients.

Full-Scale Distributors, LLC

Full-Scale Distributors, LLC is an industry leading provider of custom, private-label vaporizers through its brand, Vapor Connoisseur. The company currently serves the needs of over 80 top brands in the North American marketplace. Vapor Connoisseur is recognized for its high quality and innovative therapeutic delivery devices. Products are tailored to client needs, ensuring both safety and reliability.

Sunniva’s highly experienced management team is building partnerships with leading scientists, universities and clinical trial groups to deliver proprietary cannabis formulations to a broad spectrum of health ailments and conditions. These global partners require cGMP-certified facilities for the processing and manufacturing of cannabis products. Sunniva is committed to providing safe, pesticide-free, high quality, reproducible cannabis medicines.

Leading Sunniva is co-founder, chairman and CEO Dr. Anthony (Tony) Holler. He is the former CEO and founder of ID Biomedical, which was acquired in 2005 for $1.7 billion by GlaxoSmithKline. He is also the former chairman of Corriente Resources Inc., which was sold for approximately $700 million to CRCC-Tongguan Investment Co. Holler is currently chairman of CRH Medical Corporation, a public company trading on the TSX and NYSE. His expertise includes strategic planning, mergers and acquisitions and financing with a singular focus on increasing shareholder value.

Holler is joined by co-founder Leith Pedersen, who serves as president of Sunniva. Pedersen is the former owner and CEO of Vida Wealth Management Bahamas and was a former investment advisor at Canaccord Wealth Management. He is a former partner and director at JF Mackie and Company, an independent brokerage firm in Calgary, Alberta, that managed capital in excess of $2 billion for high net worth clients. Pedersen’s expertise is in corporate strategy, financing and mergers and acquisitions.

Sunniva, Inc. (SNNVF), closed the day's trading session at $6.6975, up 0.87%, on 41,711 volume with 178 trades. The average volume for the last 60 days is 39,360 and the stock's 52-week low/high is $6.035/$16.00.

Recent News

chart

IEG Holdings Corp. (IEGH)

The QualityStocks Daily Newsletter would like to spotlight IEG Holdings Corp. (IEGH).

IEG Holdings Corp. (OTCQB: IEGH) recently announced that shareholders of record on the measure date of April 30, 2018, will retain an upside in the cryptocurrency sector through the launch of a new cryptocurrency by Investment Evolution Coin Ltd. (“IEC”), a company managed by IEG Holdings CEO Paul Mathieson.

IEG Holdings Corp. (OTCQB: IEGH) is a publicly traded, global leader in consumer finance providing small-sized online personal loans in the United States via a state-licensed operating subsidiary, Investment Evolution Corporation, under the consumer brand “Mr. Amazing Loans.” Based in Las Vegas, the company originates consumer loans in 20 states: Alabama, Arizona, California, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland, Missouri, Nevada, New Jersey, New Mexico, Ohio, Oregon, Pennsylvania, Texas, Utah, Virginia and Wisconsin via its online platform and distribution network. IEGH is a licensed direct lender with state licenses and/or certificates of authority to lend in each state and offers all loans within the prevailing statutory rates.

Mr. Amazing Loans is a leading FinTech company specializing in dedicated loan amounts of $5,000 to $10,000 offered directly to consumers through an easy-to-use website known for its professional interaction with applicants. All loans are originated, processed and serviced out of the company’s Las Vegas corporate offices, eliminating the need for physical locations in each state where IEGH is licensed to conduct business. The company’s loans are unsecured consumer loans that mature in five years at interest rates significantly less than those of payday lenders. Consumers are able to receive same-day processing and are assured of no hidden or additional fees, no prepayment penalty, with repayment and interest rates fixed at 29.9% or less Annual Percentage Rate (APR) for the life of the loan.

The Center for Responsible Lending states the typical payday loan has rates ranging from 391% to 521% APR on loans that typically range from $100 to $1,000. Conversely, Mr. Amazing Loans’s terms are designed with low fixed repayments to fit into consumer budgets with the added goal of helping clients reach a stronger financial position. Loan funds are deposited directly into an approved consumer’s checking account and may be approved the same day after necessary application documentation is received.

IEG Holdings has also incorporated Investment Evolution Crypto, LLC., a 100 percent owned subsidiary, and tasked the new company with exploring business opportunities in the cryptocurrency/blockchain industry. Specifically, the subsidiary company will explore the legalities and economic risks of entering into a joint venture with IEGH’s other 100 percent owned subsidiary company, Investment Evolution Corporation dba Mr. Amazing Loans. Among the questions to be answered during this development planning stage are whether Mr. Amazing Loans should accept repayment of customer loans in the form of leading crypto/blockchain currencies such as Bitcoin, provide the equivalent of USD $5,000 and $10,000 loans to consumers in cryptocurrencies, and potentially create and issue an Investment Evolution cryptocurrency.

Paul Mathieson, IEG Holdings’ chairman and Chief Executive Officer, has over 19 years of finance industry experience in lending, funds management, stock market research and investment banking. He has been a member of the board of directors at IEGH since 2012 and of its subsidiary since 2009. Mathieson founded IEG Holdings Limited in Sydney, Australia, launching the Amazing Loans business in that country in 2005 and then in the United States via IEGC in 2010. He was awarded Ernst & Young’s 2007 Australian Young Entrepreneur of the Year (Eastern Region). Mathieson is joined by Carla Cholewinski, who serves as chief operating officer with over 37 years of experience in the finance industry including banking, credit union management, regulatory oversight, debt securitization and underwriting.

IEG Holdings Corp. (IEGH), closed the day's trading session at $0.26, up 10.64%, on 6,179 volume with 3 trades. The average volume for the last 60 days is 23,122 and the stock's 52-week low/high is $0.14/$4.19.

Recent News

chart

EVIO, Inc. (EVIO)

The QualityStocks Daily Newsletter would like to spotlight EVIO, Inc. (EVIO).

Legalization has analysts talking about potential shortfalls, mainly with respect to supply of the plant, but there is another less talked about issue looming: a shortage of testing labs. That has created a great growth opportunity and one that is putting EVIO, Inc. (OTCQB: EVIO), a leading provider of accredited analytical testing services for cannabis, on the map across the U.S. and now in Canada.

EVIO, Inc. (EVIO), via the EVIO Labs division, is the nation’s leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation’s cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

  • Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
  • Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
  • Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
  • Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
  • Detection of harmful residual solvents left behind in the cannabis extract production process.
  • Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
  • Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation’s leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today’s fastest growing industry.

EVIO, Inc. (EVIO), closed the day's trading session at $1.40, up 3.70%, on 112,474 volume with 122 trades. The average volume for the last 60 days is 78,174 and the stock's 52-week low/high is $0.47/$2.70.

Recent News

chart

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF)

The QualityStocks Daily Newsletter would like to spotlight Choom Holdings Inc. (CHOOF).

NetworkNewsAudio announces the Audio Press Release (APR) titled "Canadian Cannabis Growers Focus on Scaling Production," featuring Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF). To hear the NetworkNewsAudio version, visit: http://nnw.fm/iRB93. To read the original editorial, visit: http://nnw.fm/0MWqw.

Choom Holdings Inc. (OTCQB: CHOOF) (CSE: CHOO) channels the laid-back spirit of Hawaii to the Okanagan region of British Columbia with a generous nod to the inspirational, yet unofficial, history of the 1970s “Choom Gang,” a group of buddies in Honolulu (including former President Barack Obama) who knew how to relax with “choom,” the local’s term for marijuana. Choom’s trademark slogans pivot off another unconventional phrase (“Say Hello to…”), bringing a heady dose of good times and good friends together as the company invites investors to “Say Hello to Choom™” as it lights up the adult recreational cannabis market in Canada.

Choom™ has been an ACMPR (Access to Cannabis for Medical Purposes Regulations) applicant since November 2013 in Vernon, B.C. The company’s first application has received security clearance and is now in the detailed review stage. They also recently announced their second late-stage ACMPR application, which is in its confirmation of readiness stage. Cannabis Compliance Inc. has been retained to help expedite Choom’s initial license applications to ensure the company’s readiness for legalization of recreational marijuana in Canada mid-summer 2018.

True to the company’s character, Choom™ is retrofitting two large facilities – No. 1 in Vernon, B.C., and No. 2 on Vancouver Island – to house its cannabis growing facilities. Phase 1 of the Vernon property will provide Choom™ with 6,800 square feet of growing space, capable of producing 660 kg/year of cannabis at an estimated revenue of $6.6 million, excluding oils. The company expects this facility to be completed by July 2018, the same month that Canada is expected to formally legalize recreational marijuana for adult use. A potential Phase 2, to be completed by the end of 2018, would add another 6,800 square feet for a total of 1,500 kg/year capacity, which would nearly double No. 1’s revenue. A Level 9 vault is also planned with a storage capacity of 15,000 kg. While the No. 2 facility on Vancouver Island is smaller – 4,500 square feet – its retrofit is also slated to be completed by July 2018. Plans include doubling this space as well, which would add about $9 million in annual revenue, excluding cannabis oils.

Choom™ announced its retail dispensary strategy with the intention of establishing market leadership in reaching the Canadian cannabis consumer. The partner program is already in the retail space design stage as the company seeks to build a chain of branded retail cannabis dispensaries in jurisdictions in Canada where recreational cannabis is legal. Choom™ Stores will have a cool, modern layout and design created to emit an authentic “Aloha” vibe. Choom™ is all about producing high-grade cultivars and curating them for a bigger audience.

A savvy, experienced management team includes Chris Bogart, president and CEO; John Oh, R.P.I.C., Operations Manager; Robert Bayrack, Master Grower, S.P.I.C.; and Adrian Robinson, Strategic Advisor. Bogart has over two decades of international experience in capital markets and was a co-founder of InMed Pharmaceuticals and Magnum Uranium. He has structured complex equity financing transactions in the U.S., Europe and Canada. Bogart is joined on the Board of Directors by Kevin Pull, Stephen Tong and John Oh.

While the medical marijuana industry is expected to double by 2021 to 500,000 registered users, the true highlight of the recreational cannabis represents the key cultural shift set to launch in Canada. With an estimated $4.9B to $8.7B retail market coming, now is the right time for a Recreation Brand like Choom™ to be involved in this growing industry. Establishing and maintaining Choom™ premium brand loyalty is a key factor in the company’s growth strategy. Get ready to “Say Hello” to opportunity, good times and good friends with Choom™.

Choom Holdings Inc. (CHOOF), closed the day's trading session at $0.703, off by 1.68%, on 216,388 volume with 205 trades. The average volume for the last 60 days is 124,735 and the stock's 52-week low/high is $0.125/$0.8612.

Recent News

chart

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (PQEFF).

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) has developed patented clean technology for the extraction of oil from sands and shale, which disrupts existing processes. Traditional extraction processes damage the environment, require substantial capital investment and leave vast tailing ponds which take years to reclaim.

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) is a Canadian-registered, publicly traded company engaged in the development and implementation of proprietary technologies for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits. The company is focused on oil and gas exploration and production on mineral leases it owns in Texas with Accord GR Energy Inc. and in expanding production capacity at its Asphalt Ridge heavy oil extraction facility in Utah.

Petroteq Energy is also participating in a blockchain initiative aimed at solving the global transaction needs of the oil and gas industry through the development of PetroBLOQ, the Company’s collaboration formed with First Bitcoin Capital Corp. (OTC: BITCF). PetroBLOQ’s novel blockchain-based oil and gas supply chain management platform is currently being co-developed by the two companies.

PetroBLOQ recently joined the Enterprise Ethereum Alliance (“EEA”), the world’s largest open-source blockchain initiative. Membership with the 200-member EEA represents a wide variety of industries and offers 14 industry-focused, member-driven working groups.

“Joining this community of forward-looking enterprises and blockchain innovators is an important step for PetroBLOQ as we develop transformative solutions for the oil and gas industry,” said Petroteq Energy CEO Alex Blyumkin.

In addition, Petroteq has joined the American Petroleum Institute (API). The API is the only national trade association representing all facets of the oil and natural gas industry, promoting safety across the industry globally and influencing public policy in support of a strong, viable oil and natural gas industry. “API has led the development of operating standards for our industry, and we look forward to contributing our experience with oilfield technologies in addition to introducing our PetroBLOQ platform to its members throughout the supply chain,” Blyumkin previously stated.

Petroteq Energy’s patent-pending application is a closed-loop, solvent-based process, which results in significantly lower per-barrel production costs than those incurred with traditional hot water-based oil sands extraction technologies. This green technology utilizes a small, modular footprint, produces no greenhouse gases, requires no high temperatures, leaves only clean dry sand, and could be deployed to unlock heavy oil deposits located around the world.

The Company’s Asphalt Ridge mineral lease on 3,000-plus acres in northeastern Utah features a large contingent oil sands resource base with an estimated 87 million barrels of oil equivalent. In 2015, the company produced 10,000 barrels of oil from the Utah location and plans to increase production are underway. Utah holds over 32 billion barrels of undeveloped oil sands resources, which are also known as “oil-wet” deposits containing a mixture of sand and a dense, extremely viscous form of petroleum referred to as bitumen or tar. A recent upswing in developing domestic energy sources has intensified interest in technological advances such as Petroteq’s Liquid Extraction System.

The company’s Texas location includes an ownership interest (46%) in 7,000 acres under mineral leases with Accord, a Houston-based oil and gas exploration company that focuses on the development and recovery of heavy oil reserves and deposits. Two enhanced, licensed oil recovery technologies designed to increase oil recovery from more than 80 shallow oil wells on the property are expected to substantially improve the recovery rates of heavy oil deposits in this area. In both the Utah oil sands and traditional oil patch Texas project, the Company, its subsidiaries and Accord are using proprietary technologies, processes and methodologies to recover heavy oil, providing a distinct, strategic economic advantage for Petroteq Energy and its shareholders.

The Company continues to evaluate the development of other medium to heavy oil exploration, production and recovery projects on a global basis through a variety of structured agreements. These opportunities or other arrangements with private and governmental entities that utilize Petroteq Energy’s proprietary licensed technologies are expected to generate a significant return on investment.

The Company’s management team, board of directors and officers form an invaluable cross-section of industry leaders with extensive experience ranging from chemical engineering and solvent research, business development, international project management, entrepreneurial achievements, and senior management for global energy companies in North America and the Middle East. This impressive knowledge base covers both conventional and unconventional oil and gas projects and production, both in upstream and downstream industry sectors.

Petroteq Energy Inc. (PQEFF), closed the day's trading session at $0.765, off by 5.61%, on 94,498 volume with 49 trades. The average volume for the last 60 days is 146,468 and the stock's 52-week low/high is $0.015/$1.8892.

Recent News

chart

Pivot Pharmaceuticals Inc. (PVOTF)

The QualityStocks Daily Newsletter would like to spotlight Pivot Pharmaceuticals Inc. (PVOTF).

With its proven pharmaceutical and patented formulation and delivery technologies, Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) holds a favorable position in an expanding vertical of the cannabis industry. To view the full article, visit: http://cnw.fm/vdxE9.

Pivot Pharmaceuticals Inc. (OTCQB: PVOTF), based in Vancouver, Canada, is an emerging biopharmaceutical company engaged in the development and commercialization of pharmaceuticals and nutraceuticals that provide novel treatments for unmet healthcare needs. Pivot’s recent acquisition of BiPhasix ™ Transdermal Drug Delivery technology for the delivery of cannabinoids (CBD) to patients provides the answer for an age-old problem associated with cannabinoid-based therapies: the lack of a robust smoke-less delivery mechanism.

Research into the bioavailability of cannabinoid-based therapeutics shows that rates of absorption vary greatly between smoking cannabis to an orally-consumed product, with a difference noted even between individuals. Cannabinoids are degraded in the stomach and smoking may not appeal to patients for health or lifestyle reasons. Topical delivery, while a better alternative, has suffered from weak formulation issues. Transdermal cannabinoid delivery, on the other hand, could provide a better alternative route since it reduces side effects and bypasses other absorption issues. In addition, transdermal delivery provides the benefit of enabling patients to access a steady stream of medication over a prolonged period with fewer side effects.

Pivot Pharmaceutical’s newly created subsidiary, Pivot Green Stream Health Solutions Inc. (“Pivot Green Stream”), will focus on improving the bioavailability of cannabinoid-based and pharmaceuticals. BiPhasix™ has been tested in FDA and EMA approved human clinical trials, which have shown the delivery system enhances the bioavailability of many drugs and improves clinical outcomes. Pivot Green Stream is tasked with developing several natural health products containing cannabinoids (CBD) that can receive a Health Canada Natural Health Product (NHP) designation. This marketing method ensures a shorter development cycle and faster revenue generation opportunities.

Pivot Pharmaceuticals Inc., which has positioned itself as a growing and crucial vertical in the cannabis industry, represents a compelling opportunity in the biotechnology field. The company’s plans include working with Licensed Producers (LP) and Licensed Dealers (LD) to bring newer therapies to patients. The company has also applied to list on the Canadian Stock Exchange (CSE).

The global medical marijuana market is expected to reach a value of $55.8 billion by 2025, according to a new report by Grand View Research, Inc. The growing number of states and countries gaining approval for using cannabis in therapeutic applications is expected to continue driving the market forward.

Pivot Pharmaceuticals has assembled a highly experienced management team, bringing together a wealth of clinical, commercial, product development and financial experience. Among the many healthcare targets in Pivot’s pipeline are cancer supportive care, pain and inflammation, women’s sexual dysfunction, dermatology and eye disease.

Pivot Pharmaceuticals Inc. (PVOTF), closed the day's trading session at $0.3991, off by 20.18%, on 170,905 volume with 79 trades. The average volume for the last 60 days is 86,679 and the stock's 52-week low/high is $0.047/$2.46.

Recent News

chart

Medical Innovation Holdings, Inc. (OTC: MIHI)

The QualityStocks Daily Newsletter would like to spotlight Medical Innovation Holdings, Inc. (MIHI).

Medical Innovation Holdings, Inc. (MIHI), a Colorado-based publicly traded company, owns and operates strategically aligned healthcare service and product companies focused on the delivery of patient care, management services for physician offices, lab services, and pharma; and non-pharma medicines and alternatives to patients and consumers. Healthcare services are delivered and managed through the company’s MSO, 3Point Care. 3Point Care uses virtual telemedicine with a unique customized software and hardware platform as a way of bringing quality medical care to rural and medically underserved areas (MUAs) of the country.

3Point Care provides personalized high-tech, high-touch telemedicine encounters that link virtual health specialty doctors with traditional primary physicians and their patients. This approach helps reduce the cost of care while enhancing the quality of care. The company’s telemedicine approach is vastly different from other providers who rely on a monthly subscription to opt in the network and then require an encounter fee by the patient each and every time an on-demand physician is utilized. This approach breaks the continuum of care, relies on symptom-based diagnosis, does not accept insurance, and there is no certainty you are dealing with a licensed practitioner. In summation they are not a medical practice but a contract service to deliver virtual care. Because 3Point Care deploys doctors through an actual medical practice, there is no subscription fee. The company works with anyone and everyone that has insurance including Medicare and Medicaid. It works hand and hand with the patient’s primary care physician so the continuum of care is always maintained. Part of the integrated software application enables the processing of insurance claims whereby doctors are paid for their services. This allows deductibles to be captured, allowing the patients to take advantage of medical tax deductions.

TeleLifeMd, a multi-disciplinary specialty healthcare practice with strong experience in telemedicine, is the primary deliverer of patient medical care. 3Point care has a unique and exclusive relationship with TeleLifeMD, acting as its management services organization by providing all levels of service that include scheduling, providing telemedicine hardware and software products and support, processing claims, paying all invoices and payroll incurred by TeleLifeMD, as well as any other service required to operate the practice.

BKare Diagnostics, another wholly owned subsidiary of MIHI, is tasked with delivering medical and health-related services such as laboratory testing, diagnostics, and alternative medicines primarily proven nutraceuticals. Its goal is to eventually infuse these products with 100% CBD/Hemp oil and THC-based oils to create new product categories as the law catches up with the cannabis marketplace. The opportunity to offer workable solutions that solve real health problems outside typical big pharma is very exciting for the company. It sees significant revenue opportunities in this space.

MIHI firmly believes the best way to provide access to high-quality medical care is through support and delivery of evidence-based virtual medicine, commonly known as telemedicine. With 80 million people living in rural, medically underserved areas of the nation, the company is poised to fill a glaring void in the healthcare industry by applying cutting-edge technology and time-tested business practices to deliver real-time care. Among the 16 areas of medical specialties available are cardiology, infertility, gastroenterology, pediatrics and obstetrics.

The company serves a number of constituents and stakeholders interested in reducing the cost of health care while simultaneously increasing the quality of care, improving access to health services for millions of people, and bringing value to company shareholders. Its unique platform incorporates every aspect of a telemedicine visit into a single, comprehensive package.

Medical Innovation Holdings, Inc. (MIHI), closed the day's trading session at $0.087, even for the day. The average volume for the last 60 days is 54,251 and the stock's 52-week low/high is $0.05/$3.03.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.